Iterum Therapeutics plc Contracts & Agreements
79 Contracts & Agreements
- Business Finance (44 contracts)
- Business Operations (2)
- Human Resources (25)
- Intellectual Property (1)
- Uncategorized (7)
- Consulting Agreement dated August 9, 2024 between Iterum Therapeutics International Limited and Dr. Michael W. Dunne (Filed With SEC on November 14, 2024)
- Promissory Note dated October 28, 2024 from Iterum Therapeutics International Limited to Pfizer Inc (Filed With SEC on November 1, 2024)
- Consulting Agreement dated May 29, 2024 between Iterum Therapeutics International Limited and Dr. Sailaja Puttagunta (Filed With SEC on August 14, 2024)
- Form of Dealer-Manager Agreement, by and between Iterum Therapeutics plc and Maxim Group LLC (Filed With SEC on July 17, 2024)
- Form of 1-Year Warrant to Subscribe for Ordinary Shares offered by this Prospectus (Filed With SEC on July 17, 2024)
- Form of 5-Year Warrant to Subscribe for Ordinary Shares offered by this Prospectus (Filed With SEC on July 17, 2024)
- Form of 1-Year Warrant Agent Agreement, by and between Iterum Therapeutics plc and Computershare Trust Company, N.A (Filed With SEC on July 17, 2024)
- Form of 5-Year Warrant Agent Agreement, by and between Iterum Therapeutics plc and Computershare Trust Company, N.A (Filed With SEC on July 17, 2024)
- Form of Rights Certificate (Filed With SEC on July 17, 2024)
- Description of Registrant's Securities (Filed With SEC on March 28, 2024)
- Amendment to Consulting Agreement dated December 27, 2023 between Iterum Therapeutics International Limited and Dr. Michael Dunne (Filed With SEC on March 28, 2024)
- 2015 Equity Incentive Plan, as amended (Filed With SEC on November 10, 2022)
- Amended and Restated 2018 Equity Incentive Plan, as amended (Filed With SEC on November 10, 2022)
- Iterum Therapeutics plc 2021 Inducement Equity Incentive Plan, as amended (Filed With SEC on November 10, 2022)
- Consulting Agreement, dated May 25, 2022, between Iterum Therapeutics International Limited and Dr. Michael Dunne (Filed With SEC on August 12, 2022)
- Share Option Cancellation Agreement, dated July 7, 2022, between Iterum Therapeutics plc and Corey N. Fishman (Filed With SEC on August 12, 2022)
- Share Option Cancellation Agreement, dated July 7, 2022, between Iterum Therapeutics plc and Judith M. Matthews (Filed With SEC on August 12, 2022)
- Employment Terms by and between Iterum Therapeutics US Limited and Dr. Sailaja Puttagunta dated October 27, 2021 (Filed With SEC on March 28, 2022)
- Consulting Agreement dated February 21, 2021 between Iterum Therapeutics International Limited and Dr. Michael Dunne (Filed With SEC on May 14, 2021)
- Share Award Letter dated February 17, 2021 issued by Iterum Therapeutics plc to Dr. Michael Dunne and accepted by Dr. Michael Dunne on February 21, 2021 (Filed With SEC on May 14, 2021)
- Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on March 16, 2021)
- Description of Registrant's Securities (Filed With SEC on March 12, 2021)
- Securities Purchase Agreement, dated as of February 9, 2021, by and among Iterum Therapeutics plc and the purchasers party thereto (Filed With SEC on March 12, 2021)
- Form of Placement Agent Warrant (Filed With SEC on February 11, 2021)
- Form of Securities Purchase Agreement, dated February 9, 2021, by and among Iterum Therapeutics plc and the purchasers party thereto (Filed With SEC on February 11, 2021)
- Amended and Restated Underwriting Agreement, dated February 3, 2021 (Filed With SEC on February 5, 2021)
- Form of Underwriter Warrant (Filed With SEC on February 5, 2021)
- Securities Purchase Agreement, dated as of October 22, 2020, by and among Iterum Therapeutics plc and the purchasers party thereto (Filed With SEC on November 16, 2020)
- Form of Placement Agency Agreement (Filed With SEC on October 27, 2020)
- Form of Warrant (Filed With SEC on October 27, 2020)
- Form of Pre-Funded Warrant (Filed With SEC on October 27, 2020)
- Form of Placement Agent Warrant (Filed With SEC on October 27, 2020)
- Form of Securities Purchase Agreement (Filed With SEC on October 27, 2020)
- Form of Placement Agency Agreement to be entered into by and between Iterum Therapeutics plc and H.C. Wainwright & Co., LLC (Filed With SEC on October 21, 2020)
- Form of Warrant (Filed With SEC on October 21, 2020)
- Form of Pre-Funded Warrant (Filed With SEC on October 21, 2020)
- Form of Placement Agent Warrant (Filed With SEC on October 21, 2020)
- Form of Securities Purchase Agreement (Filed With SEC on October 21, 2020)
- Securities Purchase Agreement, dated as of June 3, 2020, by and among Iterum Therapeutics plc and the purchasers party thereto (Filed With SEC on August 6, 2020)
- Securities Purchase Agreement, dated as of June 30, 2020, by and among Iterum Therapeutics plc and the purchasers party thereto (Filed With SEC on August 6, 2020)
- Form of Rights Certificate (Filed With SEC on August 6, 2020)
- Form of Warrant (Filed With SEC on July 1, 2020)
- Form of Placement Agent Warrant (Filed With SEC on July 1, 2020)
- Form of Securities Purchase Agreement, dated June 30, 2020, by and among Iterum Therapeutics plc and the purchasers party thereto (Filed With SEC on July 1, 2020)
- Form of Warrant (Filed With SEC on June 4, 2020)
- Form of Placement Agent Warrant (Filed With SEC on June 4, 2020)
- Form of Securities Purchase Agreement, dated June 3, 2020, by and among Iterum Therapeutics plc and the purchasers party thereto (Filed With SEC on June 4, 2020)
- Securities Purchase Agreement, dated as of January 16, 2020, by and among Iterum Therapeutics Bermuda Limited, Iterum Therapeutics plc, Iterum Therapeutics International Limited,... (Filed With SEC on January 17, 2020)
- Form of Investor Rights Agreement, to be dated as of the Closing Date, by and among Iterum Therapeutics Bermuda Limited, Iterum Therapeutics plc, Iterum Therapeutics International... (Filed With SEC on January 17, 2020)
- First Amendment to Loan and Security Agreement, dated as of January 16, 2020, by and among Iterum Therapeutics Bermuda Limited, Iterum Therapeutics International Limited, Iterum... (Filed With SEC on January 17, 2020)
- Form of Indenture (including form of note), to be dated as of the Closing Date, by and among Iterum Therapeutics Bermuda Limited, Iterum Therapeutics plc, Iterum Therapeutics... (Filed With SEC on January 17, 2020)
- Form of Indenture (including form of note), to be dated as of the Closing Date, by and among Iterum Therapeutics Bermuda Limited, Iterum Therapeutics plc, Iterum Therapeutics... (Filed With SEC on January 17, 2020)
- 2018 Equity Incentive Plan (Filed With SEC on May 16, 2018)
- Non-Employee Director Compensation Policy (Filed With SEC on May 16, 2018)
- Amendment to Employment Agreement by and between Iterum Therapeutics US Limited and Corey N. Fishman dated May 2, 2018 (Filed With SEC on May 4, 2018)
- Amendment to Employment Agreement by and between Iterum Therapeutics US Limited and Judith M. Matthews dated May 2, 2018 (Filed With SEC on May 4, 2018)
- Loan and Security Agreement by and among Silicon Valley Bank, Iterum Therapeutics International Limited, Iterum Therapeutics US Holding Limited, and Iterum Therapeutics US... (Filed With SEC on May 4, 2018)
- Intellectual Property Security Agreement by and among Silicon Valley Bank, the Registrant, Iterum Therapeutics International Limited, Iterum Therapeutics US Holding Limited, and... (Filed With SEC on May 4, 2018)
- Warrant to Subscribe for Shares, issued to Silicon Valley Bank, dated April 27, 2018 (Filed With SEC on May 4, 2018)
- Warrant to Subscribe for Shares, issued to Life Sciences Fund II LLC, dated April 27, 2018 (Filed With SEC on May 4, 2018)
- Additional Form of Warrant to Subscribe for Ordinary Shares as may be issued to Silicon Valley Bank pursuant to the Loan and Security Agreement (Filed With SEC on May 4, 2018)
- Additional Form of Warrant to Subscribe for Ordinary Shares as may be issued to Life Sciences Fund II LLC pursuant to the Loan and Security Agreement (Filed With SEC on May 4, 2018)
- Form of Underwriting Agreement (Filed With SEC on May 1, 2018)
- Form of Ordinary Share Certificate of Registrant (Filed With SEC on May 1, 2018)
- License Agreement by and among Registrant, Iterum Therapeutics International Limited and Pfizer Inc. dated as of November 18, 2015 (Filed With SEC on May 1, 2018)
- Amended and Restated Investor Rights Agreement by and between Registrant and certain of its shareholders dated May 18, 2017 (Filed With SEC on May 1, 2018)
- 2015 Equity Incentive Plan (Filed With SEC on May 1, 2018)
- Forms of U.S. Stock Option Agreement, Stock Option Grant Notice and Notice of Exercise under the 2015 Equity Incentive Plan (Filed With SEC on May 1, 2018)
- Forms of Irish Stock Option Agreement, Stock Option Grant Notice and Notice of Exercise under the 2015 Equity Incentive Plan (Filed With SEC on May 1, 2018)
- 2018 Equity Incentive Plan (Filed With SEC on May 1, 2018)
- Forms of U.S. Stock Option Terms and Conditions and Stock Option Grant Notice under the 2018 Equity Incentive Plan (Filed With SEC on May 1, 2018)
- Forms of International Stock Option Terms and Conditions and Stock Option Grant Notice under the 2018 Equity Incentive Plan (Filed With SEC on May 1, 2018)
- Form of Restricted Share Unit Award Agreement under the 2018 Equity Incentive Plan (Filed With SEC on May 1, 2018)
- Form of Indemnity Agreement by and between the Registrant and its directors and officers (Filed With SEC on May 1, 2018)
- Form of Indemnity Agreement by and between Iterum Therapeutics US Limited and its directors and officers (Filed With SEC on May 1, 2018)
- Employment Terms by and between Iterum Therapeutics US Limited and Corey N. Fishman dated November 18, 2015 (Filed With SEC on May 1, 2018)
- Employment Terms by and between Iterum Therapeutics US Limited and Michael W. Dunne dated November 18, 2015 (Filed With SEC on May 1, 2018)
- Employment Terms by and between Iterum Therapeutics US Limited and Judith M. Matthews dated November 18, 2015 (Filed With SEC on May 1, 2018)
- Employment Terms by and between Iterum Therapeutics US Limited and Jeffrey Schaffnit dated February 9, 2018 (Filed With SEC on May 1, 2018)
